April 8, 2019 – In five years it is estimated that about 30,000 people in the United States, Europe and Japan will develop bronchiolitis obliterans syndrome (BOS), which results in respiratory failure and death. But a late-stage treatment under development by Breath Therapeutics could be a possible remedy for this rare and dread disease.